INV 001
Alternative Names: INV-001; INV-10000001Latest Information Update: 31 May 2023
At a glance
- Originator Innovo Therapeutics
- Class Skin disorder therapies; Small molecules
- Mechanism of Action HSP47 heat-shock protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase II Scars
- Preclinical Hypertrophic scars; Keloids
Most Recent Events
- 14 Feb 2023 Phase-II clinical trials in Scars (Prevention) in South Korea (Topical) (NCT05838833)
- 16 Dec 2022 Pharmacodynamics data from preclinical studies in Hypertrophic scar and Keloid released by Innovo Therapeutics (3740583
- 16 Dec 2022 Innovo Therapeutics plans to initiate phase II trial in Hypertrophic scars and Keloids in fourth quarter of 2022 (Innovo Therapeutics pipeline, December 2022)